Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
- Silvia Carreira Ribeiro,
- Ana Elizabeth Figueiredo,
- Pasqual Barretti,
- Roberto Pecoits-Filho,
- Thyago Proença de Moraes,
Am J Nephrol 2017 Jul 22;46(2):150-155. Epub 2017 Jul 22.
Background: The chronic use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker has been associated with hyperkalemia in patients with reduced renal function even after the initiation of hemodialysis. Whether such medications may cause a similar effect in peritoneal dialysis patients is not well established. So, the aim of our study was to analyze the impact of renin-angiotensin-aldosterone inhibitors on the serum levels of potassium in a national cohort of peritoneal dialysis patients. Read More